3 November 2025, 03:30 Supply: dpa Rhineland-Palatinate/Saarland
Observe
DIE ZEIT didn’t edit this record. It was once mechanically picked up via the German Information Company (dpa).
Amongst different issues, you must take a look at statements concerning the development of scientific research on most cancers remedies. (Archive photograph) © Andreas Arnold/dpa
After pronouncing a number of primary offers, pharmaceutical corporate Biontech will provide contemporary industry numbers this Monday. When the third-quarter knowledge is gifted, the folks from Mainz also are anticipated to remark at the development in their research on a number of anti-cancer medicine. The function of the corporate, which as soon as changed into well-known and wealthy with its corona vaccine, is to post an preliminary utility for approval in oncology for a kind of next-generation chemotherapy in opposition to uterine most cancers in america via the tip of 2025.
Information
Elon Musk: Tesla’s earnings fall regardless of report gross sales of electrical automobiles Auto trade: Mercedes’ earnings fell via nearly a 3rd Car trade: Porsche reported a lack of nearly a billion euros within the 0.33 quarter
In the meantime, the deliberate takeover of former Tübingen competitor Curevac is progressing. The Federal Cartel Place of work has now given the go-ahead for it and a public trade be offering is underway. Along with this industry, in June Biontech introduced cooperation with the American corporate Bristol Myers Squibb. The 2 firms agreed to collectively broaden and commercialize the drug candidate globally, for which American citizens would pay some huge cash. An in advance fee of $1.5 billion was once anticipated within the 0.33 quarter.
© dpa-infocom, dpa:251103-930-241661/1
